Colossal Biosciences reportedly in talks to raise new capital at B–B valuation

Colossal Biosciences reportedly in talks to raise new capital at $20B–$30B valuation

When de-extinction startup Colossal Biosciences revealed last year that it was attempting to “resurrect” the dire wolf from genetic material found in fossils, we argued that, despite the controversy surrounding the project, the company was building valuable technologies that justify its $10.2 billion valuation. Now, roughly 16 months later, the startup is in talks to…

Read More
#On a quest to revive the woolly mammoth, Colossal Biosciences has created a woolly mouse

#On a quest to revive the woolly mammoth, Colossal Biosciences has created a woolly mouse

Colossal Biosciences, known for its outlandish goal to resurrect the woolly mammoth by 2028, is claiming steady progress. It’s evidence: Genetically engineering mice to have mammoth-like fur. To engineer the woolly mouse, the company’s scientists found mouse versions of mammoth genes and then used CRISPR to edit mice embryos, Dr. Beth Shapiro, chief science officer…

Read More